Bone Sialoprotein Shows Enhanced Expression in Early, High-Proliferation Stages of Three-Dimensional Spheroid Cell Cultures of Breast Cancer Cell Line MDA-MB-231

Frontiers in Oncology
Valeh RustamovRüdiger Rudolf

Abstract

Normally, bone sialoprotein (BSP) is an important contributor to bone micro-calcification. However, it is also highly expressed in bone-metastatic malignancies, including prostate, lung, and breast cancer. In these disorders, BSP correlates with poor prognosis. Its expression in triple-negative breast cancer cells is enhanced by the transcription factor RUNX2, and both, BSP and RUNX2 are under control of IGF-1 and TGFβ1. Knockdown of BSP or its inactivation by specific antibodies were found to reduce the metastatic potential of MDA-MB-231 triple-negative breast cancer cells in xenografts. While the role of BSP in bone metastasis was studied using such in vivo models, valid in vitro test systems to investigate BSP biology have been lacking since this protein is expressed at very low levels in classical 2D cell cultures and the frequently used breast cancer cell line MDA-MB-231 is difficult to grow in 3D. Here, we have developed a long-term 3D spheroid culture model using MDA-MB-231 cells in a sandwich approach using cell embedding between a non-adherent surface and basement membrane extracts. This allowed consistent growth of spheroids for more than 21 days. Also, co-culturing of MDA-MB-231 with CCD-1137Sk fibroblasts yielded st...Continue Reading

References

Dec 1, 1991·Calcified Tissue International·P BiancoP G Robey
Jun 1, 1996·Endocrinology·C RaynalC Chenu
May 5, 1999·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·S J Duguay
Feb 13, 2001·Biochemical and Biophysical Research Communications·L W FisherN S Fedarko
Aug 3, 2002·Nature Reviews. Cancer·Gregory R Mundy
Jan 28, 2003·Cancer·Sanna-Maria Käkönen, Gregory R Mundy
Jun 12, 2003·Methods : a Companion to Methods in Enzymology·Jayanta DebnathJoan S Brugge
Jul 5, 2003·Cancer Cell·Yibin KangJoan Massagué
Jun 17, 2004·Journal of the National Cancer Institute·Abdullah KaradagLarry W Fisher
Aug 27, 2004·Journal of Dental Research·K U E Ogbureke, L W Fisher
Jun 16, 2005·Kidney International·Kalu U E Ogbureke, Larry W Fisher
Jun 25, 2005·Seminars in Cancer Biology·Jong Bin Kim
Sep 16, 2006·Journal of Biomolecular Screening·Andrea Ivascu, Manfred Kubbies
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert E Coleman
Aug 9, 2007·Nature Reviews. Molecular Cell Biology·Francesco PampaloniErnst H K Stelzer
Aug 28, 2007·Cell·Kenneth M Yamada, Edna Cukierman
Oct 17, 2007·Molecular Cancer Therapeutics·Lauren A KingsleyTheresa A Guise
Feb 23, 2008·Nature Reviews. Cancer·Akeila BellahcèneNeal S Fedarko
Feb 28, 2008·Journal of Periodontal Research·Y Ogata
Feb 14, 2009·Nature Protocols·Juergen FriedrichLeoni A Kunz-Schughart
May 27, 2010·The Journal of Biological Chemistry·Liza J Raggatt, Nicola C Partridge
Dec 24, 2010·Breast Cancer Research : BCR·Yu-Chi ChenAndrea M Mastro
Mar 3, 2011·International Journal of Cancer. Journal International Du Cancer·Robert R Langley, Isaiah J Fidler
May 10, 2012·Clinical Epidemiology·Shuling LiThomas J Arneson

❮ Previous
Next ❯

Citations

Feb 6, 2021·International Journal of Pharmaceutics·Nicola d'AvanzoHélder A Santos

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
antisense oligonucleotides
FCS
Protein Assay
xenograft

Software Mentioned

ImageJ
Graph Pad Prism
Excel
Graph Pad

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.